nDatalyze announces a Letter of Intent with a Pharmacogenetics company – November 09, 2023



nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces a Letter of Intent with a Pharmacogenetics company.


Calgary, Alberta – November 09, 2023

For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces that on November 8, 2023, NDAT signed a Letter of Intent (“LOI”) with Personalized Prescribing (“PP”) which LOI contemplates the addition of a DNA adjunct to NDAT’s previously-announced clinical study. The LOI anticipates a final agreement within 30 days, which agreement is to include PP’s provision of existing DNA data for up to 200 Participants in the 18-29 year age group. It is expected that Participants will complete NDAT’s biometric questionnaire with the answers combined with associated DNA data for submission to a machine-learning correlation process that is already planned for machine-learning aspect of the clinical study. Participants will be compensated by NDAT at a modest rate typical for this type of non-invasive survey.

James Durward, CEO/CTO states: “We’ve always had DNA expressions in our database and we’ve always envisioned the addition of raw DNA data that may be used as support correlation for our mental condition predictions. This relationship provides multiple tangible and intangible benefits including access to an existing DNA database where we can solicit questionnaire enrollment without having to pay the costs of DNA tests. Furthermore, PP has deep knowledge of DNA-related drug interactions and this may fit well with our goal of not only reducing misdiagnosis, but also reducing misprescriptions that often lead to poor outcomes and lower overall societal mental health.”



Personalized Prescribing is committed to developing world-leading pharmacogenetic algorithms and technology to ensure individuals receive the right drug, in the right dose, without suffering through months and, often years, of drug failure and unnecessary side effects. Their motto is: “Create a new standard of patient care in psychiatry that is based on objective data and clear science.” Personalized Prescribing’s genetic tests are covered by multiple health benefits providers. Their website is at https://personalizedprescribing.com.



YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops and to improve mental wellbeing. YMI combines machine-learning with a proprietary Reference Database that contains >1200 person’s genetic expressions, childhood environment, habits, phobias, lived experiences and lifestyle to generate a personalized graphic report predicting an individual’s predisposition toward a variety of common mental conditions, both current and forward in time.



nDatalyze Corp.
James Durward, CEO&CTO
Telephone: (403) 689-3901
Email: [email protected]

Website: www.ndatalyze.com

YMI Website: https://ymihealth.ca


Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.